Your browser doesn't support javascript.
loading
Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma.
Lian, B; Li, Z; Wu, N; Li, M; Chen, X; Zheng, H; Gao, M; Wang, D; Sheng, X; Tian, H; Si, L; Chi, Z; Wang, X; Lai, Y; Sun, T; Zhang, Q; Kong, Y; Long, G V; Guo, J; Cui, C.
Affiliation
  • Lian B; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing.
  • Li Z; Department of Pathology, Peking University Cancer Hospital and Institute, Beijing.
  • Wu N; Department of Thoracic Surgery, Peking University Cancer Hospital and Institute, Beijing.
  • Li M; Department of Gastrointestinal Surgery, Peking University Cancer Hospital and Institute, Beijing.
  • Chen X; Department of Otorhinolaryngology, Key Laboratory of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing.
  • Zheng H; Department of Gynecologic Oncology, Peking University Cancer Hospital and Institute, Beijing.
  • Gao M; Department of Gynecologic Oncology, Peking University Cancer Hospital and Institute, Beijing.
  • Wang D; Peking University School of Stomatology, Beijing.
  • Sheng X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing.
  • Tian H; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing.
  • Si L; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing.
  • Chi Z; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing.
  • Wang X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing.
  • Lai Y; Department of Pathology, Peking University Cancer Hospital and Institute, Beijing.
  • Sun T; The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China.
  • Zhang Q; The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China.
  • Kong Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing.
  • Long GV; Melanoma Institute of Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, Australia.
  • Guo J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing.
  • Cui C; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing. Electronic address: 1008ccl@163.com.
Ann Oncol ; 35(2): 211-220, 2024 Feb.
Article in En | MEDLINE | ID: mdl-37956739
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / Melanoma Limits: Humans Language: En Year: 2024 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / Melanoma Limits: Humans Language: En Year: 2024 Type: Article